]> 2026-04-12T04:14:24-07:00 BCNU (Carmustine) 0 en Considerable hepatic and pulmonary toxicity has been reported, alongside myelosuppression. The significant side effects underscore the need for careful patient monitoring and consideration of risk-benefit profiles when using BCNU in treatment regimens. 2025-01-18T08:26:18Z 2460693.8515972 BCNU (Carmustine) 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has Usefulness Explanation","While BCNU has been a standard chemotherapy treatment for GBM for decades, its efficacy, especially as a single agent in the recurrent setting, remains in question. Recent studies suggest variable PFS-6 values, indicating the need for further research and potentially more effective combination therapies."] BCNU (Carmustine)# ERR0de0b09fdf871942cb9b8a10a8978dce 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","Historically, BCNU (Carmustine) represented a cornerstone in the chemotherapy treatment of recurrent GBM, despite the absence of definitive evidence supporting its efficacy. Recent studies highlight its limited effectiveness and considerable toxicity profile when used at recurrence after radiation or Temodar failure. Comparatively, PCV (Procarbazine, Lomustine, and Vincristine) has shown some promise, albeit with considerable toxicity. These findings call for ongoing evaluation of BCNU's role in GBM treatment, exploration of effective combination therapies, and development of novel agents with improved efficacy and safety profiles."] BCNU (Carmustine)# ERRa3f62c6665776505f0db7c26c19aebf1 Has treatment name 102 en Has treatment name